BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.



Figure 1

Figure 2A



Nanocapsules prepared under different dispersion conditions.

Figure 2B



Cumulative release studies for nanocapsule formulations.

Figure 2C



Quantitative recovery of DNA from receiver solutions.

Figure 3



Nanocapsule modulation of cellular uptake.

Figure 4



Dose response for a nanocapsule formula.

Figure 5A



Nanocapsule-delivered transgene production in porcine dermis.

Figure 5B



Macromolecule delivery across keratinized barrier epithelia.

Figure 6



Incorporation of nanocapsules into a suture coating.

Figure 7A



PVP nanocapsules are taken up by fibroblasts but not keratinocytes.

Figure 7B



Nanocapsule design for tumor-targeting.

Figure 7C



Nanocapsule coating design for increased drug safety.

Figure 8A



Cellular uptake and lysosomal sequestration of RNA oligomers complexed with polyethyleneimine.

Figure 8B



Nanocapsules avoid lysosomal sequestration at 18 hours postaddition.